Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06962267 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)

Name: A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type) — clinical trial record (NCT06962267)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Started2025-04-18

View on ClinicalTrials.gov ↗

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

38 trials monitored

See all monitored trials

Pancreatic Cancer

1,634 trials monitored

See 90 trials at risk

This trial was a single-arm, open-label design to evaluate the efficacy and safety of "TQB2916+ gemcitabine + albumin-paclitaxel" as the first-line treatment for metastatic pancreatic cancer.

Trial Details

NCT Number	NCT06962267
Lead Sponsor	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions	Pancreatic Cancer
Enrollment	50 participants
Start Date	2025-04-18
Primary Completion	2027-08 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2025-05-08